(1888PressRelease)
December 11, 2008 - UROsphere is a Contract Research Organisation (CRO) that is supported by a team of pharmacologists and physiologists. It provides the pharmaceutical and biotech industries with an experimental research platform intended to assess the therapeutic potential of drug candidates.
The company offers services (preclinical studies) to assess the efficacy of drug candidates with respect to lower urinary tract pathologies including urinary incontinence, urinary tract inflammations (such as interstitial cystitis and prostatitis), benign prostate hypertrophy and sexual dysfunction, as well as kidney pathologies (diabetic nephropathy and chronic renal failure, for example). It also carries out R&D activity to implement new protocols and experimental models.
UROsphere provides its customers with innovative in-vivo physiopathological models and in-vitro pharmacological models (screening and receptor characterisation), conducted upon a wide variety of animal and human tissues. The human tissues are obtained through a partnership network with French hospitals, in compliance with regulations and laws on bioethics.
Studies and protocols are customised in order to meet each client’s needs and requirements. By involving its clients at every step of the process, UROsphere ensures that they get the responsiveness and flexibility needed to conduct each project.
Thanks to its scientific expertise and in-depth knowledge of the pharmaceutical industry, UROsphere provides its customers with high value-added consulting services and is able to offer expertise at various stages in drug development: the research phase (optimising leads or selecting the most active molecules); the preclinical development phase (preclinical proof of concept and full preclinical development plan); and the post-marketing phase, through participation during the life-cycle management.
About UROsphere
UROsphere, which is headquartered in Toulouse (in south-western France), was founded in 2004. It currently employs 15 staff (70% of whom have a PhD) and works with major international companies and pharmaceutical groups in the field of genito-urinary pathologies. The company also has a network of international scientific partners, which has enabled it to establish its expertise in the field.
UROsphere generates 80% of its turnover outside of France, 50% of which is realised within Europe. The company recorded a turnover of more than €1 million in 2007 – just three years after it was founded – an increase of over 90% on 2006.
UROsphere will take part in the Annual Meeting of the European Association of Urology, which will be held in Stockholm (Sweden) from 17 to 21 March 2009.
For further information, please go to: www.urosphere.com
###
